Holen Sie sich die Stockscreener-App
44.54
3.74%
-1.66
Schlusskurs vom Vortag:
$46.20
Offen:
$45.83
24-Stunden-Volumen:
241.84K
Relative Volume:
0.61
Marktkapitalisierung:
$2.13B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+9.08%
1M Leistung:
+5.14%
6M Leistung:
+152.11%
1J Leistung:
+0.00%
1-Tages-Spanne:
$43.26
$47.36
1-Wochen-Bereich:
$38.62
$47.36
52-Wochen-Spanne:
$6.71
$47.36
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
44.34 | 2.22B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Retail Surge: What’s the fair value of Maze Therapeutics Inc. stockQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - mfd.ru
First Week of March 20th Options Trading For Maze Therapeutics (MAZE) - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00 - Defense World
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
BTIG Research Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $46.00 - MarketBeat
Maze Therapeutics: An Innovative, Nature-Driven Platform (NASDAQ:MAZE) - Seeking Alpha
Assessing Maze Therapeutics (MAZE) Valuation After Its Recent Share Price Momentum - Sahm
What dividend safety score for Maze Therapeutics Inc. stockInflation Watch & Proven Capital Preservation Tips - Bộ Nội Vụ
Gainers Report: How Maze Therapeutics Inc stock valuations compare to rivals2025 Technical Patterns & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
How Maze Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Final Week & Risk Managed Investment Entry Signals - Улправда
How Maze Therapeutics Inc. stock valuations compare to rivalsStock Surge & Low Risk Profit Maximizing Plans - Улправда
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares - MarketBeat
Maze Therapeutics (MAZE) Stock Analysis: Exploring a 21.52% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
How rising interest rates impact Maze Therapeutics Inc. stock2025 Sector Review & Daily Momentum Trading Reports - Улправда
How Maze Therapeutics Inc. stock reacts to oil pricesJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - Улправда
Is Maze Therapeutics Inc. stock trading at a premium valuation2025 Bull vs Bear & Safe Capital Growth Stock Tips - Улправда
What sentiment indicators say about Maze Therapeutics Inc. stockQuarterly Profit Summary & Reliable Price Breakout Alerts - Улправда
Is Maze Therapeutics Inc. stock supported by innovation pipeline2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock - MarketBeat
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BERNSTEIN HAROLD Insider Trades - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Aug Patterns: How Maze Therapeutics Inc stock compares to market leadersWeekly Trade Summary & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics SVP, finance sells $606k in shares By Investing.com - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,825,200.00 in Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - marketscreener.com
Maze Therapeutics Executives Engage in Significant Stock Transactions - TradingView — Track All Markets
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
Edison Issues Report on MindMaze Therapeutics (MMTX) - TMX Newsfile
MindMaze Therapeutics (SIX: MMTX) issues 140M shares to acquire NeuroX - Stock Titan
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):